CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be? ............ 560
M. Ladanyi
Commentary on Cheung et al., p. 608

REVIEW

PI3Kα Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic .......... 562
D.A. Fruman and C. Rommel

RESEARCH BRIEFS

Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence .......... 573
Précis: An anti-MET monoclonal antibody elicited a 2-year complete response in a patient with metastatic gastric cancer with MET gene polysomy and autocrine HGF production.

A Novel Platform for Detection of CK⁺ and CK⁻ CTCs .......... 580
Précis: An expanded antibody cocktail combined with a microfluidics platform directly incorporating FISH identifies non epithelial CTCs.
ABSTRACT

A 48-year-old woman with chemorefractory metastatic gastric cancer to the liver was treated in a phase I clinical trial with MetMAb, a monoclonal antibody targeting C-Met tyrosine kinase. The patient underwent a total gastrectomy with D2 lymphadenectomy and cholecystectomy in April 2007. The primary tumor arose in a background of atrophic antral gastritis with intestinal metaplasia. After 6 cycles of biweekly FOLFOX, imaging revealed recurring disease (Fig. 1A and B). The margins were free of tumor. Postoperatively, the patient received azacitidine and enoxacin. On July 5, 2017, revealed marked thickening along the lesser curvature and a gastrohepatic ligament node. Compassionate use of MetMAb therapy at recurrence—(Fig. 2A). The margins were free of tumor. Postoperatively, the patient received azacitidine and enoxacin.

Précis: Dedifferentiated liposarcomas harbor recurring HDAC1 mutations and exhibit aberrant methylomes, suggesting that epigenetic therapies may be effective in these tumors.

Corrections

Correction: Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium ................. 626
Correction: Forty Years of Translational Cancer Research ...... 627
Correction: Drugs, Diagnostic Tests Approved Quickly .......... 627

Acknowledgment to Reviewers ........ 628

For more News and Research Watch, visit Cancer Discovery online at www.AACR.org/CDnews. Online-only News stories include the following:
• HDAC Inhibitors Show Benefits in Breast Cancer
• Phenotypic Profiling Identifies Novel Anticancer Drugs
• Automated Pathology Gives Accurate Predictions
• Triple-Acting Drug Boosts Prostate Cancer Survival
• Analyzing Intact Proteins with Mass Spectrometry
• FDA Pulls Approval for Avastin in Breast Cancer

ON THE COVER

Juergens and colleagues present results from a phase I/II trial showing that combined epigenetic therapy with azacitidine and entinostat can elicit objective responses, including one complete and one partial response, in refractory metastatic non–small cell lung cancer (NSCLC). A decreased methylation signature in response to treatment was associated with longer overall and progression-free survival, indicative of on-target epigenetic effects. Furthermore, several patients had objective responses to subsequent anticancer therapies. This combination epigenetic therapy may therefore be effective in reversing the epigenetic mechanisms driving the progression and resistance of NSCLC. For details, please see the article by Juergens and colleagues on page 598.